Business Context and Reporting Period
This Form 8-K is a current report filed by Flex Pharma, Inc. on August 23, 2017. The filing addresses corporate governance changes regarding the Board of Directors. Note: The request metadata references "Decoy Therapeutics Inc.," but the filing text explicitly identifies the registrant as Flex Pharma, Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a personnel and governance event.
Material Changes
- Board Expansion: The Board of Directors voted to increase its size to nine members.
- Director Election: William McVicar, Ph.D., the Company's President and Chief Executive Officer, was elected to the Board effective immediately.
- Term Details: Dr. McVicar was designated as a Class II member, serving until the 2020 annual meeting of stockholders or until a successor is elected.
Guidance, Outlook, and Risks
Compensation: Dr. McVicar will not receive any additional compensation for his services on the Board.
Related Party Transactions: There are no arrangements or understandings regarding his election, no family relationships with other directors or officers, and no direct or indirect material interest in transactions requiring disclosure under Item 404(a) of Regulation S-K.
Emerging Growth Company Status: The registrant is identified as an emerging growth company and has elected not to use the extended transition period for complying with new or revised financial accounting standards.
Investor Verification Checklist
- Verify the current total number of Board members (now nine).
- Confirm the term expiration date for Dr. McVicar's Class II director seat (2020 annual meeting).
- Review the Company's proxy statement for details on the remaining Board composition.
- Check subsequent filings for any changes to Dr. McVicar's executive compensation, as this filing states no additional board compensation is provided.